COMPASS Pathways (CMPS) Could Be 41% Undervalued On Phase 3 COMP360 Results

COMPASS Pathways (NasdaqGS:CMPS) just released 52 week topline data from its Phase 3 COMP005 trial, highlighting sustained efficacy, persistent clinical response, and a consistent safety profile for COMP360 in treatment resistant depression.

On the market side, COMPASS Pathways has seen strong momentum build over 2026, with a 1-day share price return of 1.32% taking the stock to US$14.54 and a year-to-date share price return of 121.98%. The 1-year total shareholder return of 182.88% and 3-year total shareholder return of 60.31% point to a powerful multi-year upswing that contrasts with a 5-year total shareholder return that is still down 53.65%. This suggests recent enthusiasm around COMP360 data is reshaping how investors view both its growth potential and risk profile.

Spot 15 high quality undiscovered gems that, like COMPASS Pathways after its COMP360 readout, could see sentiment shift sharply as clinical data or key milestones are reported.

For COMPASS Pathways, the recent surge now pits clinical progress and early revenue and earnings trends against a sharp reset in sentiment. Are buyers paying for fundamentals, or for the story around COMP360’s latest data readout?

Most Popular Narrative: 41% Undervalued

COMPASS Pathways last closed at $14.54, while the most followed narrative pegs fair value near $24.47, setting up a wide gap between price and the expectations baked into that story.

COMPASS Pathways is a mental health company developing COMP360 psilocybin treatment for conditions such as treatment resistant depression and PTSD.

Constructive interactions with both the FDA and the VA on future PTSD development, alongside finalization of a late stage PTSD protocol and selection of a CRO, expand COMP360 into a second large mental health indication. This could diversify and increase the long term revenue base and support earnings durability.

See why 8 investors see COMPASS Pathways as 41% undervalued.

Result: Fair Value of $24.47 (UNDERVALUED)

Still, the COMPASS Pathways story can change quickly if Phase 3 data disappoints or if heavier cash burn forces fresh equity raises that dilute existing holders.

Find out about the key risks to this COMPASS Pathways narrative.

Next Steps

Feeling that COMPASS Pathways is at an inflection point after this latest data and share price swing? Act quickly, review the numbers, and weigh both the upside narrative and the concerns captured in these 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond COMPASS Pathways?

If COMPASS Pathways has you rethinking what is possible in your portfolio, use that momentum and widen your opportunity set with a few focused searches.

• Target resilient balance sheets and steady fundamentals by screening companies through the list of solid balance sheet and fundamentals (23 results).
• Hunt for potential mispricings by scanning the market for 35 high quality undervalued stocks before other investors catch on.
• Prioritise stability and capital preservation by filtering for 11 resilient stocks with low risk scores that can help anchor the more speculative parts of your holdings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com